fluorouracil has been researched along with Proctitis in 18 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Proctitis: INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation proctitis was identified by imaging in 9 (15." | 2.94 | Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. ( Cheng, YK; Gao, X; Huang, XY; Lan, P; Ma, TH; Qin, QY; Wang, L, 2020) |
| "The rates of anastomotic leakage and stenosis were calculated for each treatment arm." | 2.82 | Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. ( Deng, Y; Ma, T; Qin, Q; Wang, H; Wang, J; Wang, L; Zheng, J; Zhou, Z, 2016) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | 2.79 | Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| "Transforming growth factor-beta1 is related to adverse events in radiochemotherapy." | 2.77 | Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. ( Becker, H; Beissbarth, T; Brockmöller, J; Christiansen, H; Conradi, LC; Gaedcke, J; Ghadimi, M; Hennies, S; Herrmann, MK; Hess, CF; Jo, P; Mergler, CP; Rave-Fränk, M; Schirmer, MA; Wolff, HA, 2012) |
| "Patients with T3 to T4 and/or N+ rectal cancer received preoperative IMRT (47." | 2.77 | Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. ( Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC, 2012) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| "To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy." | 1.46 | Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017) |
| "The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
| "To study the efficacy of low-dose-rate californium-252 ((252)Cf) neutron intracavitary afterloading radiotherapy (RT) combined with external pelvic RT for treatment of cervical cancer." | 1.38 | Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "Patients with inoperable rectal cancer have a remote chance of 5-year survival." | 1.27 | Ten years' experience with a multimodality treatment of advanced stages of rectal cancer. ( Wassif, SB, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YK | 1 |
| Qin, QY | 1 |
| Huang, XY | 1 |
| Lan, P | 1 |
| Wang, L | 2 |
| Gao, X | 1 |
| Ma, TH | 1 |
| Bajetta, E | 1 |
| Pietrantonio, F | 1 |
| Buzzoni, R | 1 |
| Ferrario, E | 1 |
| Valvo, F | 1 |
| Mariani, L | 1 |
| Dotti, KF | 1 |
| Biondani, P | 1 |
| Formisano, B | 1 |
| Gevorgyan, A | 1 |
| Grassi, P | 1 |
| Di Bartolomeo, M | 1 |
| Doyen, J | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Ortholan, C | 1 |
| Gérard, JP | 1 |
| Hannoun-Levi, JM | 1 |
| Gal, J | 1 |
| Francois, E | 1 |
| Gao, YH | 1 |
| An, X | 1 |
| Sun, WJ | 1 |
| Cai, J | 1 |
| Cai, MY | 1 |
| Kong, LH | 1 |
| Lin, JZ | 1 |
| Liu, GC | 1 |
| Tang, JH | 1 |
| Wu, XJ | 1 |
| Chen, G | 1 |
| Pan, ZZ | 1 |
| Ding, PR | 1 |
| Dzhugashvili, M | 1 |
| Luengo-Gil, G | 1 |
| García, T | 1 |
| González-Conejero, R | 1 |
| Conesa-Zamora, P | 1 |
| Escolar, PP | 1 |
| Calvo, F | 1 |
| Vicente, V | 1 |
| Ayala de la Peña, F | 1 |
| Osti, MF | 1 |
| Nicosia, L | 1 |
| Agolli, L | 1 |
| Gentile, G | 1 |
| Falco, T | 1 |
| Bracci, S | 1 |
| Di Nardo, F | 1 |
| Minniti, G | 1 |
| De Sanctis, V | 1 |
| Valeriani, M | 1 |
| Maglio, M | 1 |
| Borro, M | 1 |
| Simmaco, M | 1 |
| Enrici, RM | 1 |
| Qin, Q | 1 |
| Ma, T | 1 |
| Deng, Y | 1 |
| Zheng, J | 1 |
| Zhou, Z | 1 |
| Wang, H | 1 |
| Wang, J | 1 |
| Horisberger, K | 1 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 1 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 1 |
| Post, S | 1 |
| Willeke, F | 1 |
| Wenz, F | 1 |
| Hofheinz, RD | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Wolff, HA | 3 |
| Gaedcke, J | 2 |
| Jung, K | 2 |
| Hermann, RM | 1 |
| Rothe, H | 1 |
| Schirmer, M | 1 |
| Liersch, T | 1 |
| Herrmann, MKA | 1 |
| Hennies, S | 3 |
| Rave-Fränk, M | 2 |
| Hess, CF | 3 |
| Christiansen, H | 3 |
| Raus, I | 1 |
| Schüler, P | 1 |
| Herrmann, MK | 2 |
| Vorwerk, H | 1 |
| Hille, A | 1 |
| Schirmer, MA | 1 |
| Mergler, CP | 1 |
| Conradi, LC | 1 |
| Jo, P | 1 |
| Beissbarth, T | 1 |
| Becker, H | 1 |
| Ghadimi, M | 1 |
| Brockmöller, J | 1 |
| Arbea, L | 1 |
| Martínez-Monge, R | 1 |
| Díaz-González, JA | 1 |
| Moreno, M | 1 |
| Rodríguez, J | 1 |
| Hernández, JL | 1 |
| Sola, JJ | 1 |
| Ramos, LI | 1 |
| Subtil, JC | 1 |
| Nuñez, J | 1 |
| Chopitea, A | 1 |
| Cambeiro, M | 1 |
| Gaztañaga, M | 1 |
| García-Foncillas, J | 1 |
| Aristu, J | 1 |
| Zhang, M | 1 |
| Xu, HD | 1 |
| Pan, SD | 1 |
| Lin, S | 1 |
| Yue, JH | 1 |
| Liu, JR | 1 |
| Wassif, SB | 1 |
| Myerson, RJ | 1 |
| Valentini, V | 1 |
| Birnbaum, EH | 1 |
| Cellini, N | 1 |
| Coco, C | 1 |
| Fleshman, JW | 1 |
| Gambacorta, MA | 1 |
| Genovesi, D | 1 |
| Kodner, IJ | 1 |
| Picus, J | 1 |
| Ratkin, GA | 1 |
| Read, TE | 1 |
| Ernst, H | 1 |
| Stolle, E | 1 |
| Weber, P | 1 |
| Scheffler, A | 1 |
| Riedel, B | 1 |
| Gear, EV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer[NCT01211210] | Phase 2/Phase 3 | 495 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480] | 250 participants (Anticipated) | Interventional | 2018-12-17 | Recruiting | |||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Proctitis
| Article | Year |
|---|---|
Dobbins WO 3d,+DOBBINS WO III: Rectal biopsy. A review of its diagnostic usefulness.
Topics: Amyloidosis; Biopsy; Colitis, Ulcerative; Crohn Disease; Cystic Fibrosis; Cysts; Deficiency Diseases | 1968 |
8 trials available for fluorouracil and Proctitis
| Article | Year |
|---|---|
Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cohort Stu | 2020 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2012 |
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined | 2001 |
9 other studies available for fluorouracil and Proctitis
| Article | Year |
|---|---|
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; | 2014 |
Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cyclooxygenase 1; Cyclooxygenase 2; | 2014 |
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera | 2017 |
High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
High-grade acute organ toxicity as a positive prognostic factor in primary radiochemotherapy for anal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2012 |
Ten years' experience with a multimodality treatment of advanced stages of rectal cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Re | 1983 |
[Preoperative radiotherapy of bladder cancer].
Topics: Bone Marrow Diseases; Colitis; Cystitis; Elementary Particles; Fluorouracil; Humans; Mitosis; Preope | 1975 |